← Leaderboards
Timothy W Corson
Indiana University Indianapolis
$4,861,868
Attributed
$6,727,972
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,727,972 · 4
By mechanism
R01$6,581,885 · 3
T35$146,087 · 1
Top collaborators
- Mark R. Kelley4 shared
- David K Wallace3 shared
- Yoon Yeo3 shared
- Anthony Brent Daniels1 shared
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationOxygenIn VitroNeovascularizationLasersOcular NeovascularizationPreventResearch SupportEndothelial CellsMissionKnock-DownIn VivoAngiogenesis InhibitorsChoroidal NeovascularizationRetinaNeovascularProliferative Diabetic RetinopathyPublic HealthRetinal DiseasesEye DiseasesBlindnessEnzymesAngiogenesisSmall Molecule
Grant awards (18)
Long-acting formulations of griseofulvin for ocular neovascularization therapy$649,794
R01 · FY2025 · EY
Ferrochelatase as a mediator of ocular angiogenesis$377,842
R01 · FY2025 · EY · contact PI
Long-acting formulations of griseofulvin for ocular neovascularization therapy$513,683
R01 · FY2024 · EY
Ferrochelatase as a mediator of ocular angiogenesis$391,660
R01 · FY2024 · EY · contact PI
Long-acting formulations of griseofulvin for ocular neovascularization therapy$523,302
R01 · FY2023 · EY · contact PI
Targeting the Ref-1 signaling node for treating ocular neovascularization$459,194
R01 · FY2023 · EY
Ferrochelatase as a mediator of ocular angiogenesis$447,616
R01 · FY2023 · EY · contact PI
Targeting the Ref-1 signaling node for treating ocular neovascularization$445,418
R01 · FY2022 · EY · contact PI
Short-Term Training in Ophthalmology Research for Medical Students$49,067
T35 · FY2022 · EY · contact PI
Targeting the Ref-1 signaling node for treating ocular neovascularization$445,418
R01 · FY2021 · EY · contact PI
Short-Term Training in Ophthalmology Research for Medical Students$48,928
T35 · FY2021 · EY · contact PI
Ferrochelatase as a mediator of ocular angiogenesis$388,741
R01 · FY2020 · EY · contact PI
Targeting the Ref-1 signaling node for treating ocular neovascularization$374,878
R01 · FY2020 · EY · contact PI
Short-Term Training in Ophthalmology Research for Medical Students$48,092
T35 · FY2020 · EY · contact PI
Ferrochelatase as a mediator of ocular angiogenesis$388,741
R01 · FY2019 · EY · contact PI
Ferrochelatase as a mediator of ocular angiogenesis$391,616
R01 · FY2018 · EY · contact PI
Ferrochelatase as a mediator of ocular angiogenesis$393,241
R01 · FY2017 · EY · contact PI
Ferrochelatase as a mediator of ocular angiogenesis$390,741
R01 · FY2016 · EY · contact PI